"The
Report Global Chemotherapy-induced Nausea and Vomiting Drugs Market
2017-2021 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
A
recent report added to the vast research report portfolio of
MarketResearchReports.biz presents a detailed overview of the present
state of development and growth prospects over the period between
2017 and 2021 of the global chemotherapy-induced nausea and vomiting
(CINV) drugs market. The report titled “Global
Chemotherapy-induced Nausea and Vomiting Drugs Market
2017-2021,” states that the market will exhibit a promising 6% CAGR
over the said period.
The
rising preference to chemotherapy to treat a variety of cancers,
especially in developing economies such as India and China, and the
resultant rise in the prevalence of chemotherapy-induced nausea and
vomiting is considered the key factor expected to drive the market in
the near future. The low popularity of targeted therapy is also
expected to contribute to the increased preference to chemotherapy in
these countries, driving the market for CINV drugs.
The
market has been segmented on the basis of therapy into NK1 receptor
antagonists and serotonin receptor antagonists. Of these, the segment
of serotonin receptor antagonists dominated in 2016, accounting for a
leading share in the global market. These drugs operate by blocking
the binding of serotonin to its receptor, which help in stopping the
signals of vomit-stimulating from being transmitted to the brain.
Some of the commonly used serotonin antagonist drugs in the global
market are Palonosetron, Ondansetron, Tropisetron, Dolasetron, and
Granisetron.
Get Sample Copy Of This
Report @
From
a geographical point of view, the report includes detailed analysis
of the market for CINV drugs across Americas (North America and South
America), APAC (Asia Pacific), and EMEA (Europe, Middle East and
Africa). Of these, the report states that the market in Americas will
be the key contributor of revenue to the global market throughout the
forecast period. The massive rise in prevalence of cancer in the U.S.
will lead to an increased number of patients undergoing chemotherapy,
leading to the increased need for CINV drugs. The Americas CINV drugs
market will also benefit from the rising R&D activities aimed at
the development of new varieties of antiemetics.
The
global CINV drug market features a highly fragmented vendor landscape
owing to the presence of a large number of companies. Companies
compete in terms of prolonged action of the drug, its efficacy, rich
pipeline, and limited side effects. Companies are focusing on
increasing their sales through strategies such as direct sales. The
market is expected to become further competitive on account of the
rise in R&D activities and the introduction of novel therapies.
View Press Release @
http://www.marketresearchreports.biz/pressrelease/3946
Some
of the leading vendors operating in the market are GlaxoSmithKline,
Heron Therapeutics, Helsinn, Tesaro, Merck, Especificos Stendhal,
Acacia Pharma, Dr. Reddy's Laboratories, Lee’s Pharmaceutical
Holdings, Aphios, Baxter Healthcare, Ono Pharmaceutical, Orchid
Chemicals & Pharmaceuticals, F. Hoffmann-La Roche, Eisai, Purdue
Pharma, Kyowa Hakko Kirin, SciClone Pharmaceuticals, Midatech Pharma,
Mylan, OPKO Health, Otsuka Pharmaceutical, Specialised Therapeutics,
Mundipharma, Solasia Pharma K.K., Teva Pharmaceuticals, Shin Nippon
Biomedical Laboratories, Sun Pharma, and Taiho Pharmaceutical.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment